Chengdu Huasen Pharmaceutical

Huasen Pharmaceutical, officially known as Chongqing Pharscin Pharmaceutical, is a prominent Chinese pharmaceutical company specializing in the research, development, and manufacturing of both Western and traditional Chinese medicines. The company maintains a strong market presence in therapeutic areas such as gastroenterology, neuropsychiatry, and otolaryngology, with flagship products like Weidimei (Hydrotalcite) and Duliang Soft Capsules. Huasen operates advanced manufacturing facilities that meet international GMP standards and has successfully expanded its portfolio to include generic drugs and innovative formulations. Publicly traded on the Shenzhen Stock Exchange, the company continues to invest in R&D to address unmet medical needs in oncology and cardiovascular diseases.